Vir Biotechnology, Inc. Earnings Per Share (Diluted)
Vir Biotechnology, Inc. (VIR) reported Earnings Per Share (Diluted) of $0.47 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-05
- Vir Biotechnology, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was $0.47.
- Vir Biotechnology, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.85.
- Vir Biotechnology, Inc. earnings per share, diluted for the quarter ending 2025-12-31 was -$0.31.
- Vir Biotechnology, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was -$1.17.
- Vir Biotechnology, Inc. earnings per share, diluted for fiscal 2025 was -$3.16.
- Vir Biotechnology, Inc. earnings per share, diluted for fiscal 2024 was -$3.83.
- Vir Biotechnology, Inc. earnings per share, diluted for fiscal 2023 was -$4.59, a 219.84% decline from fiscal 2022.
- Vir Biotechnology, Inc. earnings per share, diluted for fiscal 2022 was $3.83, a 3.28% decline from fiscal 2021.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.47 10-Q · filed 2026-08-05 | -$0.29 10-Q · filed 2026-08-05 | -$0.58 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$1.69 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2026-03-31 | -$0.85 10-Q · filed 2026-05-07 | -$1.18 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$2.34 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$3.14 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-12-31 | -$0.31 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$1.48 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$2.28 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$3.16 10-K · filed 2026-02-23 |
| 2025-09-30 | -$1.17 10-Q · filed 2025-11-05 | -$1.98 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$2.86 10-Q · filed 2025-11-05 | -$3.62 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-06-30 | -$0.80 10-Q · filed 2026-08-05 | -$1.68 10-Q · filed 2026-08-05 | -$2.45 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$4.01 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-03-31 | -$0.88 10-Q · filed 2026-05-07 | -$1.64 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$3.21 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$4.22 derived: net income ÷ weighted average shares · filed 2026-05-07 |
| 2024-12-31 | -$0.76 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$2.33 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$3.34 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$3.83 10-K · filed 2026-02-23 |
| 2024-09-30 | -$1.56 10-Q · filed 2025-11-05 | -$2.58 derived: net income ÷ weighted average shares · filed 2025-11-05 | -$3.07 10-Q · filed 2025-11-05 | -$3.93 derived: net income ÷ weighted average shares · filed 2026-04-16 |
| 2024-06-30 | -$1.02 10-Q · filed 2025-08-06 | -$1.50 10-Q · filed 2025-08-06 | -$2.36 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$3.58 derived: net income ÷ weighted average shares · filed 2026-04-16 |
| 2024-03-31 | -$0.48 10-Q · filed 2025-05-08 | -$1.34 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$2.56 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$4.01 derived: net income ÷ weighted average shares · filed 2026-04-16 |
| 2023-12-31 | -$0.86 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$2.08 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$3.53 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$4.59 10-K · filed 2026-02-23 |
| 2023-09-30 | -$1.22 10-Q · filed 2024-11-04 | -$2.67 derived: net income ÷ weighted average shares · filed 2024-11-04 | -$3.73 10-Q · filed 2024-11-04 | -$4.47 derived: net income ÷ weighted average shares · filed 2026-04-16 |
| 2023-06-30 | -$1.45 10-Q · filed 2024-08-01 | -$2.51 10-Q · filed 2024-08-01 | -$3.26 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$1.95 derived: net income ÷ weighted average shares · filed 2026-04-16 |
| 2023-03-31 | -$1.06 10-Q · filed 2024-05-03 | -$1.81 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$0.50 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$1.07 derived: net income ÷ weighted average shares · filed 2026-04-16 |
| 2022-12-31 | -$0.75 derived: net income ÷ weighted average shares · filed 2026-04-16 | $0.55 derived: net income ÷ weighted average shares · filed 2026-04-16 | -$0.02 derived: net income ÷ weighted average shares · filed 2026-04-16 | $3.83 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.30 10-Q · filed 2023-11-03 | $0.74 derived: net income ÷ weighted average shares · filed 2023-11-03 | $4.58 10-Q · filed 2023-11-03 | $8.53 derived: net income ÷ weighted average shares · filed 2026-04-16 |
| 2022-06-30 | -$0.58 10-Q · filed 2023-08-04 | $3.28 10-Q · filed 2023-08-04 | $7.24 derived: net income ÷ weighted average shares · filed 2026-04-16 | $8.06 derived: net income ÷ weighted average shares · filed 2026-04-16 |
| 2022-03-31 | $3.85 10-Q · filed 2023-05-08 | $7.78 derived: net income ÷ weighted average shares · filed 2026-04-16 | $8.61 derived: net income ÷ weighted average shares · filed 2026-04-16 | $9.08 derived: net income ÷ weighted average shares · filed 2026-04-16 |
| 2021-12-31 | $3.93 derived: net income ÷ weighted average shares · filed 2026-04-16 | $4.75 derived: net income ÷ weighted average shares · filed 2026-04-16 | $5.21 derived: net income ÷ weighted average shares · filed 2026-04-16 | $3.96 10-K · filed 2024-02-26 |
| 2021-09-30 | $0.82 10-Q · filed 2022-11-03 | $1.29 derived: net income ÷ weighted average shares · filed 2022-11-03 | $0.02 10-Q · filed 2022-11-03 | -$0.78 derived: net income ÷ weighted average shares · filed 2023-02-28 |
| 2021-06-30 | $0.46 10-Q · filed 2022-08-09 | -$0.83 10-Q · filed 2022-08-09 | -$1.64 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$2.31 derived: net income ÷ weighted average shares · filed 2023-02-28 |
| 2021-03-31 | -$1.32 10-Q · filed 2022-05-05 | -$2.15 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$2.83 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$3.15 derived: net income ÷ weighted average shares · filed 2023-02-28 |
| 2020-12-31 | -$0.83 10-K · filed 2021-02-25 | -$1.50 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$1.80 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$2.51 10-K · filed 2023-02-28 |
| 2020-09-30 | -$0.67 10-Q · filed 2021-11-04 | -$0.96 derived: net income ÷ weighted average shares · filed 2021-11-04 | -$1.66 10-Q · filed 2021-11-04 | |
| 2020-06-30 | -$0.27 10-Q · filed 2021-08-05 | -$0.97 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | -$0.71 10-K · filed 2021-02-25 | |||
| 2019-12-31 | -$0.71 10-K · filed 2021-02-25 | -$5.76 10-K · filed 2022-02-28 | ||
| 2019-09-30 | -$4.60 10-K · filed 2021-02-25 | |||
| 2019-06-30 | -$3.64 10-K · filed 2021-02-25 | |||
| 2019-03-31 | -$3.19 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |